ERBB2 and urinary bladder cancer: Overexpression of HER2 has been observed in various adenocarcinomas, spanning breast cancer, bladder cancer, ovarian cancer, endometrial cancer, cervical cancer, lung cancer, esophageal cancer, and gastric cancer.